XenoSTART
Accelerating Translational Research for Breakthrough Oncology Treatments
Discover how our preclinical business, XenoSTART, can elevate your drug development programs with our extensive collection of over 2,500 high-quality PDX models.
Superior Patient-Derived Models: Powering Translational Research Excellence
At XenoSTART, our unique differentiation lies in our superior patient-derived xenograft (PDX) models. With the largest collection in the industry meticulously sourced from our global network of community-based oncology centers, our models serve as the foundation of our research.
Model Portfolio Highlights:
Request Access to our Catalog of Models
The Broadest Set of Indication Models in the Industry
- Adenoid Cystic Carcinoma
- Ampullary
- Bile Duct
- Bladder
- Bowel
- Brain
- Breast
- Cervix
- Chordoma
- Colorectal
- Dermatologic
- Endocrine
- Esophageal
- Gastric
- Head/Neck
- Hematologic
- Liver
- Lung
- Ovary
- Pancreas
- Penile
- Peritoneal
- Prostate
- Renal
- Sarcoma
- Uterine
- Vulva
Why Partner with XenoSTART?
01.
Unparalleled Expertise
Our team of world-class clinical investigators and research staff brings deep scientific expertise to every project, delivering high-quality results and insights.
02.
Extensive Patient-Derived Models
Boasting the largest collection of PDX models in the industry, sourced from diverse oncology centers worldwide, we provide comprehensive data across all tumor types.
03.
Cutting-Edge Facilities
Our state-of-the-art laboratories and advanced equipment support rigorous clinical pathology, treatment history analysis, and molecular characterization, ensuring the highest quality data.
04.
Streamlined Project Management
We prioritize efficient project management, clear communication, and flexibility to meet your specific needs and goals, ensuring seamless collaboration and timely results delivery.
Partnering with XenoSTART has been a game-changer for our drug development programs. Their expertise, extensive collection of patient-derived models, and commitment to operational excellence have accelerated our research and provided us with valuable insights. XenoSTART’s collaborative approach and dedication to quality make them an ideal service provider for any sponsor looking to advance their oncology research.
– Global Pharmaceutical Company
Head of Translational Research
Let's Talk
Ready to Partner with XenoSTART?
Contact XenoSTART today to discuss how our preclinical research services can support your oncology drug development programs and bring innovative treatments to patients.
